Mechanism of Action (MoA) [1]
ENERZAIR® BREEZHALER® provides comprehensive bronchodilation and on-target inflammation control1
Controlling the inflammation is the principal objective of asthma therapy. A comprehensive bronchodilation supports the ICS to reach deep into the lungs, where the inflammation resides, for an on-target inflammation control.
A comprehensive integrated solution
Watch the following to learn more about the Mode of Action (MoA) of ENERZAIR® BREEZHALER® device
ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist.
REFERENCES:
-
Price D, Fletcher M & van der Molen T. NPJ Prim Care Respir Med. 2014;24:14009.
-
Giraud V & Roche N. Eur Respir J. 2002;19:246–251.
-
Rand C. Eur Respir Rev. 2015;14:97–101.
-
NAC (National Asthma Council) Asthma Adherence. 2005. Available at: https://www.nationalasthma.org.au/living-with asthma/resources/health-professionals/information-paper/asthma-adherence [2]. Accessed: March 2020.
-
Everard M. Respir Drug Deliv. 2012;1:251–260.
-
Unwin D, et al. Respir Med. 2001;95:1006–1011.
Rate this content: